Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events

Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events

Objective: A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. A substantial part of patients treated with imatinib report skeletomuscular adverse events af...

Full description

Bibliographic Details
Main Authors: Pavel Burda, Alzbeta Hlavackova, Vendula Polivkova, Nikola Curik, Adam Laznicka, Jitka Krizkova, Jiri Suttnar, Pavel Klener, Katerina Machova Polakova
Format: Article
Language:English
Published: Elsevier 2024-10-01
Series:Molecular Metabolism
Subjects:
Imatinib
Carnitine
OCTN2
CML
TKI therapy side effects
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877824001479

Internet

http://www.sciencedirect.com/science/article/pii/S2212877824001479

Similar Items